55808 Federal Register / Vol. 75, No. 177 / Tuesday, September 14, 2010 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Nursing Research Special Emphasis Panel; 

National Research Service Award 

Institutional Research Training Grants. 

Date: October 20, 2010. 

Time: 8 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Weiqun Li, MD, Scientific 

Review Administrator, National Institute of 

Nursing Research, National Institutes of 

Health, 6701 Democracy Blvd., Ste. 710, 

Bethesda, MD 20892, (301) 594–5966, 

wli@mail.nih.gov. 

Name of Committee: National Institute of 

Nursing Research Special Emphasis Panel; 

Informed-Decision Making in Young 

Adolescent At-Risk for HIV/AIDS. 

Date: November 2, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Mario Rinaudo, MD, 

Scientific Review Officer, Office of Review, 

National Inst of Nursing Research, National 

Institutes of Health, 6701 Democracy Blvd 

(DEM 1), Suite 710, Bethesda, MD 20892, 

301–594–5973, mrinaudo@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.361, Nursing Research, 

National Institutes of Health, HHS) 

Dated: September 8, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–22832 Filed 9–13–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Nursing Research Special Emphasis Panel, 

Clinical Trial Review. 

Date: October 14, 2010. 

Time: 2 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call). 

Contact Person: Tamizchelvi Thyagarajan, 

PhD, Scientific Review Officer, National 

Institute of Nursing Reserach, National 

Institutes of Health, 6701 Democracy Blvd, 

Rm. 710, Bethesda, MD 20892, (301) 594– 

0343, tamizchelvi.thyagarajan@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.361, Nursing Research, 

National Institutes of Health, HHS) 

Dated: September 8, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–22831 Filed 9–13–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Development of AAV5 Based 

Therapeutics To Treat Human 

Diseases 

AGENCY: National Institutes of Health, 

Public Health Service, DHHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the invention 

embodied in U.S. Patent 6, 984, 517, 

entitled ‘‘AAV5 and Uses Thereof,’’ U.S. 

Patent 7, 479, 554, entitled ‘‘AAV5 

Nucleic Acids’’ and PCT Application 

Serial No. PCT/US99/11958 and foreign 

equivalents thereof, entitled ‘‘AAV5 and 

Uses Thereof’’ [HHS Ref. No. E–127– 

1998/0]; and U.S. Patent 6, 855, 314 

entitled ‘‘AAV5 Vector for Transducing 

Brain Cells and Lung Cells’’ [HHS Ref. 

No. E–072–2000/0] to Amsterdam 

Molecular Therapeutics, which is 

located in Amsterdam, The Netherlands. 

The Government of the United States of 

America has the right to license these 

patent rights. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the 

development and sale of AAV5 based 

therapeutic products to be delivered to 

the brain, eyes and liver for treatment of 

diseases originated from these organs, as 

claimed in the Licensed Patent Rights. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

October 14, 2010 will be considered. 

ADDRESSES: Requests for copy of the 

patent, inquiries, comments, and other 

materials relating to the contemplated 

exclusive license should be directed to: 

Betty B. Tong, PhD., Senior Licensing 

and Patenting Manager, Office of 

Technology Transfer, National Institutes 

of Health, 6011 Executive Boulevard, 

Suite 325, Rockville, MD 20852–3804; 

Telephone: (301) 594–6565; Facsimile: 

(301) 402–0220; E-mail: 

tongb@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

technology describes an adenoassociated virus 5 (AAV5), vectors and 

particles derived from the virus; as well 

as methods of delivering nucleic acids 

to a cell by using the AAV5 vectors and 

particles. More specifically, the 


jlentini on DSKJ8SOYB1PROD with NOTICES